News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Announces Initial Public Offering

BOULDER, Colo., Nov. 17 /PRNewswire/ -- Array BioPharma, Inc. (Nasdaq: ARRY) today announced the pricing of an initial public offering of 6.5 million shares of common stock at $7.50 per share. All of the shares are being offered by Array BioPharma. The initial public offering is being underwritten by Lehman Brothers Inc., Deutsche Banc Alex. Brown, and Legg Mason Wood Walker, Incorporated.

Array BioPharma intends to use the net proceeds from the offering to fund its operations, including continued development and manufacturing of existing products as well as research and development of additional products and services, hiring additional personnel and expanding its facilities. A portion of the proceeds may be used to acquire or invest in new products or technologies, pay down debt or acquire complementary businesses. The balance of the proceeds will be used to fund working capital and for general corporate purposes.

Array BioPharma is a discovery research company creating drug candidates through innovations in chemistry. Array's scientists provide premium drug discovery products and services to create, evaluate and optimize potential drug candidates in collaboration with pharmaceutical and biotechnology companies. Array's information-based approach is designed to improve the efficiency of the drug discovery process and increase the quality of potential drug candidates. Array also applies its drug discovery capabilities internally for its own drug discovery programs. For additional information, visit Array's web site at www.arraybiopharma.com.

Copies of the prospectus relating to the offering may be obtained from Lehman Brothers Inc., 3 World Financial Center, New York, New York 10285, 212-526-7000; Deutsche Banc Alex. Brown, One South Street, Baltimore, Maryland 21202, 410-727-1700; Legg Mason Wood Walker, Incorporated, 100 Light Street, Baltimore, Maryland 21202, 410-539-0000.

This press release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. SOURCE Array BioPharma, Inc.

CONTACT: Joanna K. Money, Ph.D., Director, Business Development of Array BioPharma, Inc., 303-381-6676, jmoney@arraybiopharma.com/